Transcend Capital Advisors’s Teva Pharmaceuticals TEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $229K | Buy |
13,692
+973
| +8% | +$16.3K | 0.02% | 539 |
|
|
2025
Q1 | $195K | Sell |
12,719
-35
| -0.3% | -$538 | 0.01% | 574 |
|
|
2024
Q4 | $281K | Buy |
12,754
+32
| +0.3% | +$705 | 0.02% | 457 |
|
|
2024
Q3 | $229K | Buy |
12,722
+76
| +0.6% | +$1.37K | 0.02% | 545 |
|
|
2024
Q2 | $205K | Buy |
12,646
+196
| +2% | +$3.19K | 0.01% | 556 |
|
|
2024
Q1 | $176K | Sell |
12,450
-93
| -0.7% | -$1.31K | 0.01% | 507 |
|
|
2023
Q4 | $131K | Buy |
12,543
+1,500
| +14% | +$15.7K | 0.01% | 487 |
|
|
2023
Q3 | $113K | Hold |
11,043
| – | – | 0.01% | 472 |
|
|
2023
Q2 | $83.2K | Hold |
11,043
| – | – | 0.01% | 478 |
|
|
2023
Q1 | $97.7K | Sell |
11,043
-1,900
| -15% | -$16.8K | 0.01% | 468 |
|
|
2022
Q4 | $118K | Buy |
12,943
+93
| +0.7% | +$848 | 0.01% | 474 |
|
|
2022
Q3 | $104K | Hold |
12,850
| – | – | 0.01% | 464 |
|
|
2022
Q2 | $97K | Hold |
12,850
| – | – | 0.01% | 479 |
|
|
2022
Q1 | $121K | Buy |
12,850
+1,900
| +17% | +$17.9K | 0.01% | 497 |
|
|
2021
Q4 | $88K | Sell |
10,950
-150
| -1% | -$1.21K | 0.01% | 476 |
|
|
2021
Q3 | $104K | Sell |
11,100
-547
| -5% | -$5.13K | 0.01% | 477 |
|
|
2021
Q2 | $114K | Buy |
11,647
+547
| +5% | +$5.35K | 0.02% | 318 |
|
|
2021
Q1 | $128K | Hold |
11,100
| – | – | 0.02% | 402 |
|
|
2020
Q4 | $107K | Hold |
11,100
| – | – | 0.01% | 368 |
|
|
2020
Q3 | $100K | Buy |
+11,100
| New | +$100K | 0.02% | 255 |
|
|
2020
Q2 | – | Sell |
-10,950
| Closed | -$98K | – | 190 |
|
|
2020
Q1 | $98K | Buy |
+10,950
| New | +$98K | 0.03% | 204 |
|